History | Carfilzomib for previously treated multiple myeloma | Guidance | NICE

History

Documents created during the development process.

Final draft guidance: TA657

Final draft guidance: TA657
Final appraisal document - TA657 (PDF 333 KB)

Published:

16 October 2020
Stakeholder matrix - TA657 (PDF 160 KB)

Published:

16 October 2020

Review proposal consultation: (2) TA657

Review proposal paper (2) - TA657 (PDF 189 KB)

Published:

12 May 2020
Stakeholder matrix (2) - TA657 (PDF 160 KB)

Published:

12 May 2020

Review proposal consultation: (1) TA657

Review proposal paper (1) - TA657 (PDF 264 KB)

Published:

10 January 2019
Stakeholder matrix (1) - TA657 (PDF 261 KB)

Published:

08 January 2019

Expected publication

Equality Impact Assessment (Guidance development) - TA457 (PDF 248 KB)

Published:

19 July 2017

Final draft guidance: TA457

Final appraisal document - TA457 (PDF 539 KB)

Published:

09 June 2017
Committee papers - TA457 (PDF 6.63 MB)

Published:

09 June 2017
Public committee slides - TA457 (PDF 355 KB)

Published:

09 June 2017

Draft guidance: TA457

Appraisal consultation document (PDF version) - TA457 (PDF 414 KB)

Published:

09 November 2016

Invitation to participate

Final scope - TA457 (PDF 107 KB)

Published:

19 May 2016
Final stakeholder list - TA457 (PDF 99 KB)

Published:

19 May 2016
NICE's response to comments on the draft scope and provisional stakeholder list - TA457 (PDF 159 KB)

Published:

19 May 2016
Equality impact assessment (Scoping) - TA457 (PDF 121 KB)

Published:

19 May 2016

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: TA457

Draft scope post referral - TA457 (PDF 112 KB)

Published:

04 April 2016
Draft matrix post referral - TA457 (PDF 99 KB)

Published:

04 April 2016